Pomerantz Law Firm Investigates Alnylam Pharmaceuticals Following Significant Stock Price Decline
Pomerantz LLP has launched an investigation into Alnylam Pharmaceuticals, Inc. (ALNY) to determine if the company or its executives engaged in securities fraud or unlawful business practices. The probe follows a sharp decline in the company's stock price after it reported third-quarter financial results for the period ending September 30, 2026. The investigation is centered on reports of slowing demand for Amvuttra, a transthyretin-mediated amyloidosis treatment that constitutes 87.5% of Alnylam's total product sales. Specifically, U.S. total transthyretin demand growth was reported at $81 million, a significant decrease from the $129 million recorded in the previous quarter. Following these disclosures on October 29, 2026, Alnylam's stock price plummeted by $58.40, representing a 25.13% loss to close at $174.00.
Tickers: $ALNY
Topics: class action lawsuit earnings report impact securities fraud investigation stock price decline
Read the full article at PR Newswire
Part of the story Pomerantz Law Firm Investigates Potential Securities Fraud at Intel Corporation (3 articles)